2020& 61 2020 korean society of …icksh.org/data/icksh2020_leaflet.pdf2020 korean society f...

2020 KOREAN SOCIETY OF HEMATOLOGY INTERNATIONAL CONFERENCE & 61st ANNUAL MEETING2020

MARCH 12 - 14, 2020Grand Walkerhill Hotel, Seoul, Koreawww.icksh.org

2020 Korean Society of Hematology INTERNATIONAL CONFERENCE & 61st ANNUAL MEETING March 12 - 14, 2020 Grand Walkerhill Hotel, Seoul, Korea

WELCOME MESSAGE

Dear Colleagues and Friends,

On behalf of the Organizing Committee, it is with great delight that we welcome you to the 2020 KSH International Conference &

61st Annual Meeting, hosted by the Korean Society of Hematology (KSH), in Seoul, Korea, March 12 to 14, 2020.

The Korean Society of Hematology successfully held the second ICKSH last year attracting over 1300 attendees from 41 countries.

With the goal of making ICKSH2020 another successful meeting, the Organizing Committee has prepared an exciting and

informative congress program providing a unique opportunity to learn about the most recent findings and research from renowned

specialists as well as to exchange ideas and information with colleagues for the continued success and progress of our field.

Our programs will include topics such as benign hematologic diseases, various types of hematologic malignancies, coagulation/

thrombosis related disorders and transfusion medicine through plenary lectures, as well as scientific and education sessions. In

addition, a variety of stimulating social programs has been planned so participants can enjoy the fascinating Korean culture and share

our warm spirit of friendship.

We welcome your support and look forward to seeing you at ICKSH 2020 in Seoul, Korea!

Chan-Jeong Park

Congress ChairmanThe Korean Society of Hematology

Bin Cho

PresidentThe Korean Society of Hematology

March 12 - 14, 2020 Grand Walkerhill Hotel, Seoul, Korea

KEY SPEAKERS

March 12 (Thu.) Plenary Lectures I – Cutting Edge of Emerging Therapies

Cutting edge of emerging therapies : Oncolytic virusDavid H. KirnUniversity of California, BerkeleyUSA

T cell and gene therapy Helen HeslopBaylor College of MedicineUSA

March 13 (Fri.)Plenary Lectures II – Clinical Hematology Lecture

Translational cancer research in B-cell malignanciesJohn GribbenBarts Cancer InstituteUK

Myelodysplastic Syndrome and

Predisposition to Myeloid Neoplasia

in Children and AdolescentsCharlotte NiemeyerUniversity of FreiburgGermany

March 14 (Sat.)Plenary Lectures III – Genomics in Hematologic Malignancies

Latest treatment developments in multiple myeloma Nikhil MunshiDana-Farber Cancer InstituteUSA

Genetic Alterations in Relapsed/

Refractory AML: Is There Something

Special?Hyeoung-Joon KimChonnam National University Medical SchoolKorea

Presidential Symposium

The evolution of acute leukemia diagnostics and its place in treatmentElizabeth MacintyreNecker-Enfants Malades HospitalFrance


PROGRAM _MARCH 12 (Thu.), 2020

ROOM A ROOM B ROOM C ROOM D

08:00-09:00 REGISTRATION

08:50-09:00 OPENING

09:00-10:30

[JS01]KAI-KSH JOINT SESSION

- IMMUNOTHERAPEUTICS IN BLOOD DISEASE

[SS01]STEM CELL BIOLOGY

Role of PD-1 on regulatory T cells in modulating immunity during cancer progression

(Sang-Ju Ha, Korea)

Regulation of anti-tumor immunity by IL-17 producing T cells(Yeon Seok Chung, Korea)

TBD(Young-Woo Jeon, Korea)

DC-based therapeutic approaches for treatment of multiple myeloma

(Manh-Cuong Vo, Vietnam)

Molecular and cellular constituents of the stem cell

niche (Paul Frenette, USA)

Microenvironmental changes in malignancies of the bone marrow

through the single-cell lens (Ninib Baryawno, Sweden)

Microenvironmental regulation of hematopoietic stem cell

quiescence and self-renewal(Lev Silberstein, USA)

10:30-10:45 Coffee Break

10:45-11:45

PLENARY LECTURE ICUTTING EDGE OF EMERGING THERAPIES

Cutting edge of emerging therapies : Oncolytic virus(David H. Kirn, USA)

T cell and gene therapy(Helen Heslop, USA)

11:45-12:45

PRESIDENTIAL SYMPOSIUM

The evolution of acute leukemia diagnostics and its place in treatment(Elizabeth Macintyre, France)

12:45-13:40 LUNCHEON SYMPOSIUM

13:40-14:40

[AS01]CUTTING EDGE THERAPEUTIC

APPROACHES IN CML

[AS02]UPDATES OF HEMATOLOGIC

DISEASE IN ASIAN POPULATION

From Korean perspective(Dong-Wook Kim, Korea)

From Chinese perspective(Qian Jiang, China)

From Japanese perspective(Shinya Kimura, Japan)

Thalassemia treatment in Indonesia

(Tubagus Djumahan Atmakusuma, Indonesia)

Hemophilia Treatment in Singapore

(Tien Sim Leng, Singapore)

Thalassemia treatment in Malaysia

(Jameela Sathar, Malaysia)


PROGRAM _MARCH 12 (Thu.), 2020


14:55-16:25

[JS02]KOGO-KSH JOINT SESSION - GENOMICS FOR PRECISION

HEMATOLOGY

[SS02]B-CELL LYMPHOMA

[SS03] ACUTE LYMPHOBLASTIC

LEUKEMIA

[ES01]ACUTE MYELOID LEUKEMIA

Transcriptional programs associated with aggressive

myeloma progression(Hae-Ock Lee, Korea)

DNA methylation landscape and tumor heterogeneity in

leukemia(Sun kim, Korea)

Clinical Application of Next-Generation Sequencing in Acute Myeloid Leukemia

(Jae Sook Ahn, Korea)

Next-Generation Sequencing in Hematologic Malignancies

(Miyoung Kim, Korea)

Genomic landscape of DLBCL(Laura Pasqualucci, USA)

Immunotherapy for Hodgkin lymphoma

(John Kuruvilla, Canada)

Optimal treatment strategy for double-hit lymphoma

(Lorenz Trumper, Germany)

Contemporary treatment of pediatric Ph+ ALL

(Kirk Schult, Canada)

Current treatment approaches to newly diagnosed adult ALL (in context of risk stratifiation

and molecular subtype)(Daniel J. DeAngelo, USA)

Results of high risk and novel subtypes of pediatric ALL in

Japan(Katsuyoshi Koh, Japan)

Classification of AML(Sang Mee Hwang, Korea)

Treatment of children and adolescents with AML

(Hyery Kim,Korea)

New agents in AML(Silvia Park, Korea)


16:40-18:10

[SS04]MULTIPLE

MYELOMA

[SS05]ACUTE MYELOID

LEUKEMIA/ MYELODYSPLASTIC

SYNDROME

[SS06]ADVANCES

IN TECHNOLOGY

[ES02]ACUTE LYMPHOBLASTIC

LEUKEMIA

Novel Strategies to Overcome Relapsed/Refractory Multiple

Myeloma(Suzanne Trudel, Canada)

MRD negativity - the foremost important goal of myeloma

treatment?(Bruno Paiva, Spain)

Diagnosis and treatment of primary amyloidosis

(Giampaolo Merlini, Italy)

Genomic data and risk assessment beyond the 2017

ELN recommendations(Hartmut Döhner, Germany)

BCL-2 as a stem cell target in AML

(Daniel A. Pollyea, USA)

TGF- ß pathway: its role in MDS pathogenesis and

treatment application (Uwe Platzbecker, Germany)

Big data in hematology: HARMONY

(Jesús María Hernández Rivas, Spain)

Intelligent Image-Activated Cell Sorting: Principles and Application to Hematology

(Akihiro Isozaki, Japan)

Incorporating genetics into clinic

(Elli Papaemmanuil, USA)

Minimal residual disease in acute lymphoblastic

leukemia: technical aspects and implications for clinical

interpretation(In-Suk Kim, Korea)

ALL in adolescents and young adults

(Jae Wook Lee, Korea)

Ph+ ALL(Han Seoung Park, Korea)

18:30-20:00 WELCOME RECEPTION

SESSION CODE[JS] Joint Symposium [SS] Scientific Session [ES] Educational Session[AS] Asian Hematology Symposium [LS] Luncheon Symposium [MS] MOU Country Session



08:00-09:00 REGISTRATION

09:00-10:30

[JS03]EHA-KSH

JOINT SYMPOSIUM I - BASIC

[SS07]THROMBOTIC

MICROANGIOPATHIES

[SS08]BENIGN HEMATOLOGY

[ES03]MULTIPLE MYELOMA

The Evil Side of Gene Regulation in AML(Ruud delwel, The

Netherlands)

Clonal Evolution under IDH Inhibitor Therapy in Acute

Myeloid Leukaemia(Lynn Quek, UK)

TBD(Korea)

TTP(Marie Scully, UK)

Post Transplant Thrombotic Microangiopathy

(Vahid Afshar-Kharghan, USA)

Pediatric HUS(Shuichi Ito, Japan)

Novel treatment for ITP(Cindy E. Neunert, USA)

Management recommendations for

hereditary hemolytic anemia(Hannah Tamary, Israel)

Recent understandings of congenital neutropenia

(Julia Skokowa, Germany)

Frontline therapy for newly diagnosed multiple myeloma

(Sung-Hoon Jung, Korea)

Treatment of relapsed/refractory multiple myeloma

(Ji Hyun Lee, Korea)

AL amyloidosis: advance in diagnosis and management

(Youngil Koh, Korea)


10:45-11:45

PLENARY LECTURE IICLINICAL HEMATOLOGY LECTURE

Translational cancer research in B-cell malignancies(John Gribben, UK)

Myelodysplastic Syndrome and Predisposition to Myeloid Neoplasia in Children and Adolescents

(Charlotte Niemeyer, Germany)

11:45-12:45

[MS01]MOU COUNTRY

SESSION 1

POSTER PRESENTATION

Outcome of Autologous Transplant in T Cell

Lymphoma: Experience of NIHBT in Vietnam

(Nguyen Vu Bao Anh, Vietnam)

Subcutaneous Panniculitis-like T-cell Lymphoma

(Udomsak Bunworasate, Thailand)

Update of Extranodal NK/T-cell lymphoma: Treatment

and Biology(Seok Jin Kim, Korea)

12:45-13:40 LUNCHEON SYMPOSIUM

PROGRAM _MARCH 13 (Fri.), 2020



13:40-14:55 ORAL SESSION I

14:55-15:10 Break

15:05-16:20 ORAL SESSION II

16:25-16:40 Break

16:40-18:10

[SS09]BONE MARROW FAILURE

SYNDROME

[SS10]CELL THERAPY/

TRANSPLANTATION

[SS11]SUPPORTIVE CARE

[ES04]LYMPHOMA

Challenges in the diagnosis of bone marrow failure

syndromes: the role of genetic panels?

(Ghulam J Mufti, UK)

Clonal hematopoesis in bone marrow failure

(Daria V. Babushok, USA)

Treatment algorithm in AA: the past, present and future

(Shinji Nakao, Japan)

CAR T for AML: Developing AML-Specific Anti-CD33 CAR

T Cells by Gene Editing(Saar Gill, USA)

Immune Escape and Relapse after Allogeneic

Hematopoietic Cell Transplantation

(Luca Vago, Italy)

HSCT: Alloreactivity in Haploidentical Stem Cell

Transplantation with Post-Cy(Christopher G. Kanakry, USA)

For improve palliative care and outcomes in low- and middle-

income countries (Scott Howard, USA)

Chemotherapy-induced peripheral neuropathy in

patients with hematologic malignancies

(Guido Cavaletti, Italy)

Vaccinations before/after biologic agents in

patients with hematologic malignancies

(Per Ljungman, Sweden)

Primary CNS lymphoma(Yoon Seok Choi, Korea)

NK/T cell lymphoma(Seong Hyun Jeong, Korea)

Recent advances in CLL therapy

(Jieun Uhm, Korea)

18:10-18:30

18:30-20:00 GALA DINNER


PROGRAM _MARCH 13 (Fri.), 2020


PROGRAM _MARCH 14 (Sat.), 2020


07:20-08:20 BUSINESS MEETING

08:30-09:00 WORKING PARTY REPORTS

09:00-10:30

[JS04]EHA-KSH

JOINT SYMPOSIUM II - CLINICAL

TRANSLATIONAL

[SS12]T-CELL LYMPHOMA /HD

[SS13]PEDIATRIC DISEASE

Clinical Developments of Bcl-2/Mcl-1 Targeting

(Marion Subklewe, Germany)

TBD(Korea)

Emerging Role of MRD in AML

(Gert Ossenkoppele, The Netherlands)

TBD(Korea)

PD-L1 and NK/T-cell lymphoma

(Won Seog Kim, Korea)

Novel agents for PTCL(Francine Foss, USA)

Biology of AITL(Mamiko Sakata-Yanagimoto,

Japan)

RAS/MAPK pathways in JMML

(Mignon Loh, USA)

The role of RAS mutation in relapsed ALL

(Julie Irving, UK)

RAS/MAPK pathways in histiocytosis

(Carl Allen, USA)


10:45-11:45

PLENARY LECTURE IIIGENOMICS IN HEMATOLOGIC MALIGNANCIES

Latest treatment developments in multiple myeloma (Nikhil Munshi, USA)

Genetic Alterations in Relapsed/Refractory AML: Is There Something Special?(Hyeoung-Joon Kim, Korea)

11:45-12:30 AWARD CEREMONY & CLOSING



KEY DATES

SEP 162019

Call for AbstractsRegistration Open

DEC 272019

Deadline forAbstract Submission

JAN 62020

Notification ofAbstract Acceptance

FEB 152020Deadline

for Early-bird Registration

CALL FOR ABSTRACT

The ICKSH 2020 Organizing Committee cordially invites you to submit abstracts for oral and poster presentations. All conference abstracts must be submitted online via the Online Submission System (www.icksh.org). Submitted abstracts will be reviewed by the Scientific Program Committee. The presentation type may be changed following review by the Scientific Committee.Only outstanding selected abstracts will be reviewed on-site for the Best Presentation Award. Therefore, please submit your abstracts carefully.

Important Dates

DEC 27, 2019 (UTC/GMT-11) Deadline for Abstract SubmissionJAN 6, 2020 (UTC/GMT-11) Notification of Abstract Acceptance

Abstract Submission Topics· Acute lymphoblastic leukemia· Acute myeloid leukemia· Anemia and other red cell disorders· Basic science· Bone marrow failure syndromes· Cellular therapy· Chronic myeloid leukemia· Cytopenia· Hematopoiesis· Hematopoietic stem cell transplantation

· Hemostasis· Histiocytosis· Laboratory hematology· Lymphoma· Myeloproliferative neoplasm· Multiple myeloma· Myelodysplastic syndrome· Platelet· Stem cell biology· Thrombosis


REGISTRATION

All participants are requested to register via the Online Submission System (www.icksh.org) and advised to register in advance to receive the Pre-Registration discount by February 15, 2020.Registrants who completed payment are able to download the invitation letter from the online system (www.icksh.org). However, registration does not guarantee the applicant a visa.

Registration FeesCategory Pre-Registration

(by February 15, 2020)On-Site Registration

(from February 16, 2020)

OVERSEAS General USD 100 USD 200

Resident/ Trainee/ Nurse/ Student USD 50 USD 100

DOMESTIC KSH Member KRW 100,000 KRW 200,000

Non-Member KRW 200,000 KRW 300,000

Student/Resident KRW 50,000 KRW 50,000

Fellow/Trainee/Nurse KRW 50,000 KRW 100,000

* Registration fee includes access to all scientific programs, exhibition, coffee break, lunch, welcome reception and gala dinner.

* Students are requested to submit proof of enrollment or student ID/certificate to verify their status to the Secretariat by e-mail.

Payment- Payment by credit card is possible only through the on-line registration system.- Direct bank transfers should be made to the account below. All bank charges for remittance must be paid by the registrants.

Overseas· Account Number: 1307-020-107652· Bank Name: THE KWANGJU BANK, LTD.· Bank Address: 15F., Kwangju Bank Bldg., 7-12, Daen-dong, Dong-gu, Kwangju, 501-730, Korea· Swift Code: KWABKRSE· Account Holder: ICKSH

Domestic

· 은행명: 광주은행

· 계좌번호: 1107-020-382364

· 예금주: 대한혈액학회 국제학술대회


TRAVEL GRANT

Travel Grant will be awarded to especially presenters from low-income countries up to 100 participants. Travel grants will be given to presenters whose abstracts have been accepted. Awardees will receive a travel grant in the amount of USD 1,000 or 1,500.Download the application form on the ICKSH website and return the application form to the ICKSH 2020 Secretariat via e-mail ([email protected]) by December 27, 2019.

Eligibility1. Presenters of accepted abstracts are eligible for the travel grant.2. Abstracts must be presented by awardees at ICKSH 2020.3. Presenters need to register for the conference. (Registration fees will not be waived.)4. Participants from low-income economies, lower-middle-income economies or upper-middle-income economies qualify as classified by the World Bank. Eligible countries is notice at the ICKSH2020 website (www.icksh.org).

Date & Time18:30-20:00 March 12

VenueRE: Bar, Vista Walkerhill Seoul (1F)

FeeIncluded in the registration fee

MenuStanding Cocktail

Date & Time18:30-20:00 March 13

VenueWalkerhill Theater, Grand Walkerhill (B1)

FeeIncluded in the registration fee

MenuWestern Full Course

Welcome Reception Gala Dinner

SOCIAL PROGRAM

2020 Korean Society of Hematology INTERNATIONAL CONFERENCE & 61st ANNUAL MEETING

VenueGrand Walkerhill Hotel04963) Walkerhill Hotel, 177 Walkerhill-ro, Gwangjin-gu, Seoul, KoreaTel. +82-2-455-5000 www.walkerhill.com/grandwalkerhillseoul

ICKSH 2020 Secretariat1F, Haeoreum B/D, 16, Yeoksam-ro 17 gil, Yeoksam-dong, Gangnam-gu, Seoul, Korea Tel. +82-2-566-6031, 6033 Fax. +82-2-566-6087 E-mail. [email protected]

TRENDY AND HISTORICAL SEOUL!

From old to new, explore all that the city has to offer. Visit the best shopping districts, top historical sites, and panoramas with the best views of the city skyline. Whether you prefer modern architecture or the charm of the royal palaces, there is something for everyone!

Top 5 Attractions

1 Dongdaemun Market A huge shopping district where you can find almost anything!

4 Insa-dongExperience Korea's traditional charm through food and shopping.

2 Myeongdong Seoul's shopping Mecca is filled with beauty outlets, malls, street stalls, and more.

5 N Seoul TowerOne of the most popular locations to experience breath-taking views of Seoul.

3 Gyeongbokgung PalaceThe first royal palace built during the Joseon dynasty.

2020& 61 2020 korean society of …icksh.org/data/icksh2020_leaflet.pdf2020 korean society f...

Documents